PL1610822T3 - Płynne formulacje farmaceutyczne FSH i LH z niejonowym surfaktantem - Google Patents

Płynne formulacje farmaceutyczne FSH i LH z niejonowym surfaktantem

Info

Publication number
PL1610822T3
PL1610822T3 PL04725385T PL04725385T PL1610822T3 PL 1610822 T3 PL1610822 T3 PL 1610822T3 PL 04725385 T PL04725385 T PL 04725385T PL 04725385 T PL04725385 T PL 04725385T PL 1610822 T3 PL1610822 T3 PL 1610822T3
Authority
PL
Poland
Prior art keywords
fsh
freeze
liquid
pharmaceutical formulations
ionic surfactant
Prior art date
Application number
PL04725385T
Other languages
English (en)
Other versions
PL1610822T5 (pl
Inventor
Fabrizio Samaritani
Piergiorgio Donati
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33135521&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1610822(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Publication of PL1610822T3 publication Critical patent/PL1610822T3/pl
Publication of PL1610822T5 publication Critical patent/PL1610822T5/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
PL04725385T 2003-04-02 2004-04-02 Płynne formulacje farmaceutyczne FSH i LH z niejonowym surfaktantem PL1610822T5 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP03100882 2003-04-02
EP03101543 2003-05-27
EP03101828 2003-06-20
PCT/EP2004/050432 WO2004087213A1 (en) 2003-04-02 2004-04-02 Liquid pharmaceutical formulations of fsh and lh together with a non-ionic surfactant
EP04725385.1A EP1610822B2 (en) 2003-04-02 2004-04-02 Liquid pharmaceutical formulations of fsh and lh together with a non-ionic surfactant

Publications (2)

Publication Number Publication Date
PL1610822T3 true PL1610822T3 (pl) 2011-06-30
PL1610822T5 PL1610822T5 (pl) 2019-05-31

Family

ID=33135521

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04725385T PL1610822T5 (pl) 2003-04-02 2004-04-02 Płynne formulacje farmaceutyczne FSH i LH z niejonowym surfaktantem

Country Status (24)

Country Link
US (1) US7741268B2 (pl)
EP (1) EP1610822B2 (pl)
JP (1) JP4699991B2 (pl)
KR (1) KR101105486B1 (pl)
AR (1) AR043972A1 (pl)
AT (1) ATE492292T2 (pl)
AU (1) AU2004226666B9 (pl)
BR (1) BRPI0409532B8 (pl)
CA (1) CA2518903C (pl)
CY (1) CY1111291T1 (pl)
DE (1) DE602004030673D1 (pl)
DK (1) DK1610822T4 (pl)
EA (1) EA012565B1 (pl)
HR (1) HRP20100727T4 (pl)
IL (1) IL171151A (pl)
ME (1) ME00217B (pl)
MX (1) MXPA05010635A (pl)
NO (1) NO330214B1 (pl)
NZ (1) NZ542247A (pl)
PL (1) PL1610822T5 (pl)
PT (1) PT1610822E (pl)
RS (2) RS57872B1 (pl)
SI (1) SI1610822T2 (pl)
WO (1) WO2004087213A1 (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY139088A (en) * 2005-02-21 2009-08-28 Lg Life Sciences Ltd Sustained release composition of protein drug
TWI369401B (en) * 2005-07-05 2012-08-01 Ares Trading Sa Serum-free culture medium for the production of recombinant gonadotropins
PL1951395T3 (pl) 2005-09-14 2012-08-31 Ares Trading Sa Sposób ilościowego oznaczania poloksamerów
KR101105871B1 (ko) * 2005-09-27 2012-01-16 주식회사 엘지생명과학 인 난포자극호르몬의 안정한 용액 제형
NZ583991A (en) * 2007-11-01 2012-02-24 Merck Serono Sa Luteinizing hormone liquid formulations
BRPI0908887B8 (pt) 2008-02-08 2021-05-25 Biogenerix Ag composição farmacêutica líquida, recipiente farmacêutico, e, métodos para preparar e para fabricar uma composição farmacêutica
CN101269215B (zh) * 2008-05-15 2011-03-23 上海天伟生物制药有限公司 一种糖蛋白激素组合物
CN102309747B (zh) * 2008-09-17 2013-04-17 上海天伟生物制药有限公司 高纯度绝经期促性腺素冻干针剂
CA2742659C (en) * 2008-11-04 2016-09-27 Aska Pharmaceutical Co., Ltd. Aqueous composition containing follicle-stimulating hormone
CN102448979B (zh) 2009-04-01 2015-03-04 拉蒂奥法姆有限责任公司 纯化重组促卵泡激素的方法
EP2325194A1 (en) 2009-11-24 2011-05-25 Glycotope GmbH Process for the purification of glycoproteins
CN102100908B (zh) 2009-12-22 2013-05-08 上海天伟生物制药有限公司 一种蛋白质组合物
WO2012127500A2 (en) * 2011-03-11 2012-09-27 Sanzyme Limited Composition for spermatogenesis
WO2014159813A1 (en) 2013-03-13 2014-10-02 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
HK1223559A1 (zh) * 2013-11-12 2017-08-04 Cadila Healthcare Limited 用於促性腺激素的配方
JP6647220B2 (ja) * 2014-05-23 2020-02-14 インスティトゥート・マッソーネ・エセ・ア Ｈｍｇ−ｕｐ（超高純度グレードのヒト閉経期ゴナドトロピン）を得るための方法及び夾雑物を含まない組成物
US11376220B2 (en) 2017-06-30 2022-07-05 Therio, LLC Single-injection methods and formulations to induce and control multiple ovarian follicles in bovine, caprine, ovine, camelid and other female animals
TWI865430B (zh) * 2017-07-24 2024-12-11 美商再生元醫藥公司 穩定化之抗體組合物及其製法

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB839300A (en) 1957-09-05 1960-06-29 Organon Labor Ltd Adrenocorticotropic hormone preparations and process for making same
GB1065127A (en) 1963-03-11 1967-04-12 Serono Ist Farm Pituitary gonadotropic hormone preparation and method for its production
EP0082481B2 (en) * 1981-12-23 1990-09-12 Schering Corporation Stabilised alpha-interferon formulations and their preparation
JPS5921613A (ja) * 1982-07-28 1984-02-03 Takeda Chem Ind Ltd 直腸投与製剤
US4659696A (en) * 1982-04-30 1987-04-21 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its nasal or vaginal use
US4746508A (en) * 1983-06-06 1988-05-24 Beth Israel Hospital Assn. Drug administration
US5639639A (en) * 1983-11-02 1997-06-17 Genzyme Corporation Recombinant heterodimeric human fertility hormones, and methods, cells, vectors and DNA for the production thereof
US4839341A (en) * 1984-05-29 1989-06-13 Eli Lilly And Company Stabilized insulin formulations
US4589402A (en) * 1984-07-26 1986-05-20 Serono Laboratories, Inc. Method of in vitro fertilization
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US4780451B1 (en) 1987-01-23 1995-04-04 Asua International Inc Composition and method for producing superovulation in cattle
US5162306A (en) * 1987-01-23 1992-11-10 Donaldson Lloyd E Composition and method for producing superovulation in mammals
IT1206302B (it) * 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
EP0318081B1 (en) * 1987-11-27 1991-07-24 Akzo N.V. Stabilization of antibodies
US5096885A (en) 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
US5087615A (en) * 1989-03-17 1992-02-11 Applied Research Systems Ars Holding N.V. Novel method of ovulation induction in humans
US5733572A (en) * 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US5384132A (en) * 1990-03-20 1995-01-24 Akzo N.V. Stabilized gonadotropin containing preparations
US5270057A (en) * 1990-03-20 1993-12-14 Akzo N.V. Stabilized gonadotropin containing preparations
IE64738B1 (en) * 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
US5374620A (en) * 1990-06-07 1994-12-20 Genentech, Inc. Growth-promoting composition and its use
DE4117078A1 (de) 1991-05-25 1992-11-26 Boehringer Ingelheim Kg Verfahren zur herstellung therapeutisch anwendbarer aerosole
US5508261A (en) * 1991-06-18 1996-04-16 University Of Medicine & Dentistry Of New Jersey Analogs of glycoprotein hormones having altered receptor binding specificity and activity and methods for preparing and using same
EP0673383B1 (en) 1991-06-18 2000-05-31 University Of Medicine & Dentistry Of New Jersey Analogs of glycoprotein hormones having altered receptor binding specificity and activity and methods for preparing and using same
IT1250075B (it) * 1991-12-18 1995-03-30 Serono Cesare Ist Ricerca Composizioni farmaceutiche contenenti gonadotropine.
US5356876A (en) * 1992-01-13 1994-10-18 Trinity University Methods of terminating pregnancy
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
EP0652766B2 (en) 1992-07-31 2008-03-19 Genentech, Inc. Human growth hormone aqueous formulation
US5661125A (en) * 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
JP3946246B2 (ja) * 1993-02-02 2007-07-18 ゾーマ・コーポレイション 殺菌性／浸透性増大タンパク質（Ｂａｃｔｅｒｉｃｉｄａｌ／Ｐｅｒｍｅａｂｉｌｉｔｙ Ｉｎｃｒｅａｓｉｎｇ ｐｒｏｔｅｉｎ：ＢＰＩ）及び界面活性剤を含有する医薬組成物
US6238890B1 (en) * 1994-02-18 2001-05-29 Washington University Single chain forms of the glycoprotein hormone quartet
US5594091A (en) 1994-02-21 1997-01-14 Takeda Chemical Industries, Ltd. Matrix for sustained-release preparation
US5580856A (en) * 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
PT801571E (pt) * 1994-12-22 2002-12-31 Ortho Pharma Corp Formulacoes soluveis de 2-cloro-2'-desoxiadenosina
US6524557B1 (en) * 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
ES2159726T3 (es) * 1995-03-10 2001-10-16 Roche Diagnostics Gmbh Formas de administracion farmaceuticas que contienen polipeptidos, en forma de microparticulas, y procedimiento para su fabricacion.
TW426523B (en) 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
FR2733914B1 (fr) * 1995-05-11 1997-08-01 Sanofi Sa Composition de liquide stable contenant de l'urate oxydase et composition lyophilisee pour sa preparation
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
PT1516628E (pt) 1995-07-27 2013-09-24 Genentech Inc Formulação de proteína liofilizada isotónica estável
TR199800811T2 (xx) 1995-11-07 1998-07-21 Genentech,Inc. NGF i�in stabilize edici form�lasyonlar.
IL130432A0 (en) * 1996-12-23 2000-06-01 Novo Nordisk As A medicament container of polymer of cyclic hydrocarbon for storing a liquid medicament
US6136784A (en) * 1997-01-08 2000-10-24 Amylin Pharmaceuticals, Inc. Amylin agonist pharmaceutical compositions containing insulin
EP1015493A1 (en) 1997-01-10 2000-07-05 EPIcyte Pharmaceutical, Inc. Novel epithelial tissue targeting agent
TW518235B (en) * 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
US20010007673A1 (en) * 1999-11-12 2001-07-12 Merrill Seymour Goldenberg Sustained-release delayed gels
US6113947A (en) * 1997-06-13 2000-09-05 Genentech, Inc. Controlled release microencapsulated NGF formulation
US6287587B2 (en) 1997-07-15 2001-09-11 Takeda Chemical Industries, Ltd. Process for producing sustained-release preparation by in-water drying
ATE232087T1 (de) 1997-10-27 2003-02-15 Merck Patent Gmbh Feste lösungen und dispersionen von eines schlecht wasserlöslichen wirkstoffes
ZA9811127B (en) 1997-12-09 2000-07-11 Lilly Co Eli Stabilized teriparatide solutions.
US6541606B2 (en) * 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
US20020165146A1 (en) * 1998-07-23 2002-11-07 Hoffman James Arthur FSH article of manufacture
KR20010083126A (ko) * 1998-07-23 2001-08-31 피터 지. 스트링거 여포자극 호르몬 및 여포자극 호르몬 변이체 제형, 제품및 방법
FR2782455B3 (fr) 1998-08-20 2000-09-15 Sanofi Sa Composition pharmaceutique injectable a base d'un sel pharmaceutiquement acceptable du clopidogrel ou de ticlopidine
JP2002524514A (ja) * 1998-09-17 2002-08-06 イーライ・リリー・アンド・カンパニー タンパク質製剤
EP1191099B1 (en) 1999-06-30 2009-10-07 Takeda Pharmaceutical Company Limited Novel polypeptide and dna thereof
US6573237B2 (en) * 2001-03-16 2003-06-03 Eli Lilly And Company Protein formulations
WO2003066585A2 (en) 2002-02-08 2003-08-14 Alkermes Controlled Therapeutics, Inc. Polymer-based compositions for sustained release

Also Published As

Publication number Publication date
HK1086503A1 (en) 2006-09-22
CY1111291T1 (el) 2015-08-05
EA200501531A1 (ru) 2006-06-30
US7741268B2 (en) 2010-06-22
PT1610822E (pt) 2011-01-05
AU2004226666B9 (en) 2010-04-08
MXPA05010635A (es) 2005-12-12
KR101105486B1 (ko) 2012-01-13
EP1610822B1 (en) 2010-12-22
PL1610822T5 (pl) 2019-05-31
ME00217B (me) 2011-02-10
DE602004030673D1 (de) 2011-02-03
BRPI0409532A (pt) 2006-04-18
SI1610822T1 (sl) 2011-02-28
DK1610822T4 (en) 2019-01-14
BRPI0409532B1 (pt) 2019-09-17
IL171151A (en) 2014-11-30
DK1610822T3 (da) 2011-01-31
CA2518903A1 (en) 2004-10-14
EP1610822A1 (en) 2006-01-04
AU2004226666B2 (en) 2009-09-03
KR20050110037A (ko) 2005-11-22
JP4699991B2 (ja) 2011-06-15
US20060147480A1 (en) 2006-07-06
RS20050737A (sr) 2007-11-15
HRP20100727T4 (hr) 2018-11-16
ATE492292T2 (de) 2011-01-15
SI1610822T2 (sl) 2018-12-31
NO20054982L (no) 2005-10-26
HRP20100727T1 (hr) 2011-02-28
EP1610822B2 (en) 2018-09-19
WO2004087213A1 (en) 2004-10-14
AR043972A1 (es) 2005-08-17
NO330214B1 (no) 2011-03-07
EA012565B1 (ru) 2009-10-30
BRPI0409532B8 (pt) 2021-05-25
NZ542247A (en) 2008-03-28
WO2004087213A8 (en) 2005-03-17
MEP31708A (en) 2010-10-10
JP2006522072A (ja) 2006-09-28
CA2518903C (en) 2013-02-05
RS57872B1 (sr) 2018-12-31
AU2004226666A1 (en) 2004-10-14

Similar Documents

Publication Publication Date Title
PL1610822T5 (pl) Płynne formulacje farmaceutyczne FSH i LH z niejonowym surfaktantem
PT1757606E (pt) Utilização de derivados de xantina como produto farmacêutico, bem como seu processo de preparação
SI1478339T1 (sl) Farmacevtske formulacije antineoplastičnih sredstev, zlasti temozolomida, postopki za pripravo in uporabo le-teh
IL159025A0 (en) Hydrophobic dopamine agonists administered to the dermis
HUP0302482A3 (en) Novel surfactants and aqueous pesticide formulations
AU2002328343A1 (en) Wax-based compositions and the use thereof as body care agents
PL388076A1 (pl) Doustna postać dawki o przedłużonym uwalnianiu oksykodonu i jej zastosowanie
GB0107795D0 (en) Camera with visible and infra-red imaging
ZA200300316B (en) Rapidly decomposing administrable form for releasing active ingredient in the oral cavity or in body cavities.
ZA200502496B (en) Ester compound and medicinal use thereof.
IL150383A0 (en) Glyburide and pharmaceutical compositions containing the same
GB0104980D0 (en) Liquid cleaning compositions and their use
HUP0400515A3 (en) Synergetic active agent combinations with insecticidal and acaricidal properties preparation and use thereof
HUP0401911A3 (en) Pesticidal formulations and their use
PL366851A1 (pl) Preparaty złożone pochodnych 1,1-ditlenku 1,4-benzotiepiny i dalszych substancji czynnych oraz ich zastosowanie
GB0101035D0 (en) Formulation and use thereof
HUP0303454A3 (en) Solid pharmaceutical composition comprising 4-cyano-trifluoro-3(4-fluorophenyl-sulphonyl)-2-hydroxy-2-methylpropiono-m toluidide and pvp
IT1321215B1 (it) Dispositivo per la movimentazione e l'orientamento degli ugellispruzzatori in una bassina .
HUP0402318A3 (en) Pharmaceutical composition comprising cyclosporin and use thereof
ZA200306545B (en) Medicinal compositions comprising diclofenac and ornoprostil.
EP1439315A4 (en) COMPOSITION FOR USE AS SELF-BLOCKING AGENT AND THIS USING SELF-BLOCKING LINK
GB0004714D0 (en) The joy ball
GB2364640B (en) Anti-ulcer pharmaceutical composition and the preparation thereof
ZA200300055B (en) Anthelminthic agents for the prevention of parasitic infections in humans and animals II.
HUP0301579A3 (en) Anthelminthic composition for the prevention of parasitic infections in humans and animals and use thereof